STERIS stock trades near its yearly high as earnings and outlook support valuation

STERIS stock is trading close to its recent high, supported by solid revenue and earnings growth in fiscal 2025 as the medical-technology group (ISIN IE00BFY8C754) continues to expand its infection prevention and sterilization portfolio across North America and internationally.

Revenue up double digits in fiscal 2025

STERIS plc, listed on the New York Stock Exchange, reported that revenue for its fiscal year 2025, which ended on 31 March 2025, increased by around ten percent compared with fiscal 2024, driven by demand for sterilization systems, consumables, and healthcare infection prevention services according to publicly available investor information.

Within this performance, adjusted earnings per share for fiscal 2025 rose compared with the prior year, reflecting operating leverage in core businesses and continued cost discipline; the company highlighted that higher-margin consumables and services contributed to the improvement in profitability, based on its latest financial communications to investors.

Margin trends and comparison with prior year

According to the most recent annual data, STERIS achieved year-on-year growth in operating income in fiscal 2025 alongside the roughly ten percent increase in revenue, implying a positive change in operating margin versus fiscal 2024 and supporting the company’s ability to invest in new capacity and innovation.

Management indicated in its fiscal 2025 commentary that cash flow from operations improved versus the prior year, providing additional flexibility for capital expenditure and shareholder returns, while net debt remained manageable relative to earnings; this combination of margin expansion and cash generation underpins the company’s current valuation framework.

Infection prevention products support growth

STERIS generates a significant share of its revenue from infection prevention, decontamination, and sterilization products and services used by hospitals, surgical centers, and pharmaceutical manufacturers, and demand for these offerings has continued to underpin the company’s double-digit revenue growth in fiscal 2025.

The company’s portfolio includes sterilizers, washers, consumables, and integrated service contracts that create recurring revenue streams; the traction of these solutions in North America, Europe, and other markets supports the view that STERIS can sustain mid- to high-single-digit organic growth over the medium term, complemented by targeted acquisitions.

STERIS stock price and market context

STERIS stock is traded on the New York Stock Exchange, and recent data from major financial portals indicate that the shares have been changing hands near the upper end of their 52-week range, with a market capitalization in the mid- to high-single-digit billions of dollars as of mid 2026.

For investors, the combination of roughly ten percent revenue growth in fiscal 2025, higher earnings per share compared with fiscal 2024, and the share price trading close to its yearly high highlights how operating performance and expectations for continued infection prevention demand are reflected in STERIS valuation metrics.